$NTHI News

Last published 14h ago

14h agoNTHINeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 TrialGlobeNewswireRecent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100
15h agoNTHINeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data PresentationsGlobeNewswireNew insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators
1d agoNTHI INLF CRWV OMHBrain Cancer Breakthrough Hopes, a $30 Million Robotics Deal and an AI Gold RushGlobeNewswire$NTHI, $INLF, $CRWV, and $OMH are among today’s best stocks in the news
1d agoNTHIFDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster TrackGlobeNewswireNeOnc (NASDAQ: NTHI) secured an FDA Type B End-of-Phase meeting, early January 2027, to discuss a potential accelerated approval pathway for NEO100
1d agoNTHINeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100GlobeNewswireNeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal
3d agoNTHINeOnc CEO Adds Another 70,000 Shares as Insider Buying ContinuesGlobeNewswireDALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for
3d agoNTHINeOnc CEO Adds Another 70,000 Shares as Insider Buying ContinuesGlobeNewswireNeOnc’s (NASDAQ:NTHI) CEO purchased another 70,000 shares of NTHI, according to a newly filed SEC Form 4.
1w agoNTHINEONC TECHNOLOGIES HOLDINGS, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
1w agoNTHINeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressGlobeNewswireCALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for
1w agoLCUT NTHI PLCE CABOFour Elevated Short Interest Stocks as Oil Retreats and Midterm Elections ApproachGlobeNewswireDENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- (247MarketNews.com) — Lifetime Brands (NASDAQ:LCUT), NeOnc Technologies Holdings (NASDAQ:NTHI), The Children's Place (NASDAQ:PLCE), and Cable One (NYSE:CABO) offer four
1w agoNTHINeOnc Is Putting Two Brain Cancer Programs on the Global StageGlobeNewswireDENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) -- (247MarketNews.com) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is developing a story that could
1w agoNTHINeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-OncologyGlobeNewswireCALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for
1w agoNTHINeOnc’s Ambitious Brain Cancer Plans are Setting the StageGlobeNewswireDENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- (247MarketNews.com) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing something
2w agoGENB BMY NTHI AZN2027 Could Finally Be the Year Cancer Is on the Ropes!GlobeNewswireDENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
2w agoNTHI AVBP XNCRDefining Moments in the Race for Biotech BreakthroughsGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major
2w agoNTHINeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three CountriesGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial
2w agoNTHINeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts ContinueGlobeNewswireDENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially important technical
3w agoPFE NTHI AVTR LLYHealthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth ChapterGlobeNewswireDENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE:PFE) is drawing renewed attention to
3w agoNTHINeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the SpotlightGlobeNewswireDENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) is taking its brain cancer research story to a national television audience at a moment when several
3w agoNTHINeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic ChemotherapyGlobeNewswireCALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for
3w agoNTHI NBIX ACAD AVXL+1Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar MarketGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
3w agoNTHINeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves ForwardGlobeNewswireDENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — "I wish someone had told me about that company." That is a familiar reaction when a stock attracts attention after investors have spent months
3w agoNTHINeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical CollaborationGlobeNewswireProposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi Two children
3w agoNTHIForget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst SeasonGlobeNewswireDENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- At an ugly-sweater party, the one with the most flair gets everyone talking. On Wall Street, attention can shift just as quickly when a battered chart
3w agoNTHINeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use MilestoneGlobeNewswireDENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding
3w agoNTHINeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu DhabiGlobeNewswireCALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for
4w agoNTHI PZZA TSLAFrom Shaq to Musk: The Power Appointment EffectGlobeNewswireDENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The right appointment can do more than fill a board seat. It can change a company’s public profile, open doors to new partnerships, reshape its
4w agoNTHIUAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development AdvancesGlobeNewswireDENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings (NASDAQ:NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development strategy. The
4w agoNTHINeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026GlobeNewswireCALABASAS, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies
4w agoNTHINeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug DevelopmentGlobeNewswireDENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some
4w agoNTHINeOnc Technologies Appoints Ali Alabedin to Its Board of DirectorsGlobeNewswireCALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for
1mo agoNTHI MRNA MRK JNJ2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New HopeGlobeNewswireDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
1mo agoNTHINeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against CancerGlobeNewswireDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
1mo agoNTHINeOnc’s FDA Catalyst Run Could Give NTHI a Serious JoltGlobeNewswireDENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A fall calendar is bringing NeOnc Technologies Holdings’ (NASDAQ:NTHI) investigational brain-cancer programs into focus. Anticipation is building as
1mo agoNTHINeOnc Charting New Nasal Route to Treating Brain CancerGlobeNewswireDENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings’ (NASDAQ:NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because
1mo agoAEMD NTHI BIAF TURBFour High-Impact Small Caps Enter the SpotlightGlobeNewswireDENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical
1mo agoNTHINeOnc Eliminates Major Dilution Risk as Clinical Story AcceleratesGlobeNewswireDENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies (NASDAQ:NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 outstanding shares of
1mo agoNTHINeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential DilutionGlobeNewswireCALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing
1mo agoNTHINeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDAGlobeNewswireDENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its
1mo agoNTHINeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a ResultsGlobeNewswireCALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing
1mo agoNTHIInvestor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in FocusGlobeNewswireDALLAS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- The Chief Executive Officer of NeOnc Technologies Holdings (NASDAQ:NTHI), Amir F. Heshmatpour has purchased another 37,000 shares of the company’s
1mo agoNTHIInsiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory TestGlobeNewswireDENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is sending investors a signal that is impossible to ignore. The company's CEO, President and director,
2mo agoNVS NTHI TNON IRDBig Pharma Setbacks Create a New Wave of Rebound PlaysGlobeNewswireDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker
2mo agoNTHI IRD BIAF TNONFour Biotech Stories Heating Up Right NowGlobeNewswireDENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies
2mo agoNTHINeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 DataGlobeNewswireDENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and
2mo agoNTHINeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional InvestorsGlobeNewswireCALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing
2mo agoNTHINeOnc' Phase 2 Data Could Put Cancer on the RopesGlobeNewswireDENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ:NTHI), the Phase 2a question has been answered. Now comes the question that could matter even more to the
2mo agoNTHINeOnc’s Phase 2A Success Could Set the Stage for Something Much BiggerGlobeNewswireDENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ:NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent
2mo agoNTHINeOnc’s Clinical Story Is Now the Main EventGlobeNewswireDENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100’s
2mo agoNTHINeOnc Technologies- Talk Is Cheap, Insider Buying Isn’tGlobeNewswireDENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is